Compare IXHL & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IXHL | VNRX |
|---|---|---|
| Founded | 2001 | N/A |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.6M | 31.9M |
| IPO Year | 2024 | 2012 |
| Metric | IXHL | VNRX |
|---|---|---|
| Price | $3.25 | $0.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.50 |
| AVG Volume (30 Days) | ★ 4.1M | 1.5M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.00 |
| EPS | ★ N/A | N/A |
| Revenue | $12,000.00 | ★ $1,233,511.00 |
| Revenue This Year | N/A | $68.22 |
| Revenue Next Year | N/A | $382.75 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 59.10 |
| 52 Week Low | $0.11 | $0.17 |
| 52 Week High | $6.39 | $0.94 |
| Indicator | IXHL | VNRX |
|---|---|---|
| Relative Strength Index (RSI) | 56.41 | 36.92 |
| Support Level | $0.31 | $0.17 |
| Resistance Level | $5.17 | $0.27 |
| Average True Range (ATR) | 0.51 | 0.02 |
| MACD | 0.09 | 0.00 |
| Stochastic Oscillator | 49.82 | 17.93 |
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.